Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOY SCHECHTMAN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1649244716
CMS profile
165768
Location
PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$140,240.74

395 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 8; records 101–150 of 395 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOY SCHECHTMAN

NPI 1649244716 · CMS profile ID 165768

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

PEORIA, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 8; records 101–150 of 395 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649244716?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOY SCHECHTMAN, NPI 1649244716, CMS profile ID 165768. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 395 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649244716?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOY SCHECHTMAN, NPI 1649244716, CMS profile ID 165768. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 8; records 101–150 of 395 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649244716?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOY SCHECHTMAN, NPI 1649244716, CMS profile ID 165768, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 8; records 101–150 of 395 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1649244716?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

395 matching records · $140,240.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 395 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 395.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $16.2010/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944935483 CMS
Janssen Scientific Affairs, LLC $1,125.0010/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887178337 CMS
Janssen Scientific Affairs, LLC $1,000.0010/19/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887178343 CMS
UCB, Inc. $2.5210/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170975 CMS
ABBVIE INC. $24.0710/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535297 CMS
Amgen Inc. $15.3810/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779163 CMS
Novartis Pharmaceuticals Corporation $19.1910/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894333849 CMS
ABBVIE INC. $1,000.0010/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535295 CMS
Amgen Inc. $2,200.0010/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779151 CMS
Exeltis, USA Inc. $15.9010/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947108521 CMS
UCB, Inc. $12.7710/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908113403 CMS
UCB, Inc. $33.1310/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170983 CMS
AstraZeneca Pharmaceuticals LP $17.8810/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915880103 CMS
Amgen Inc. $57.1310/04/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779147 CMS
Amgen Inc. $17.8110/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939272389 CMS
UCB, Inc. $60.0010/03/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908037511 CMS
UCB, Inc. $27.9010/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170979 CMS
Alexion Pharmaceuticals, Inc. $16.6109/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915666633 CMS
Amgen Inc. $14.1709/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939272367 CMS
PFIZER INC. $21.9909/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949344387 CMS
ABBVIE INC. $1,500.0009/27/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535293 CMS
PFIZER INC. $11.8709/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949342247 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $1,690.0009/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887454069 CMS
Janssen Biotech, Inc. $20.9509/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885507951 CMS
ABBVIE INC. $29.1209/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535291 CMS
Horizon Therapeutics plc $2,448.0009/21/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937687851 CMS
GlaxoSmithKline, LLC. $16.2009/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944935491 CMS
Lilly USA, LLC $25.4809/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918106699 CMS
Amgen Inc. $25.3909/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779127 CMS
Horizon Therapeutics plc $124.9809/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937687845 CMS
Horizon Therapeutics plc $2,448.0009/15/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937687847 CMS
Horizon Therapeutics plc $9.2509/15/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937687849 CMS
Novartis Pharmaceuticals Corporation $15.1509/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894333845 CMS
ABBVIE INC. $750.0009/12/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535289 CMS
UCB, Inc. $28.3209/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908037481 CMS
AstraZeneca Pharmaceuticals LP $23.5809/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915001453 CMS
Amgen Inc. $2,200.0009/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779143 CMS
Aurinia Pharma U.S., Inc. $24.2009/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954103547 CMS
Alexion Pharmaceuticals, Inc. $19.3309/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915160617 CMS
Janssen Biotech, Inc. $21.7409/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885507905 CMS
AstraZeneca Pharmaceuticals LP $3,700.0008/31/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915527093 CMS
ABBVIE INC. $750.0008/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535287 CMS
Amgen Inc. $2,200.0008/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779135 CMS
Amgen Inc. $23.6308/30/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933779139 CMS
Radius Health, Inc. $13.3008/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954934699 CMS
AstraZeneca Pharmaceuticals LP $14.8008/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915210635 CMS
GlaxoSmithKline, LLC. $18.0608/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944935489 CMS
PFIZER INC. $2.9008/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949321891 CMS
Amgen Inc. $13.0308/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939272387 CMS
ABBVIE INC. $26.8408/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891535283 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $191,415.40 562
PY2020 $84,073.56 295
PY2021 $57,746.90 271
PY2022 $140,240.74 395
PY2023 $124,415.64 345
PY2024 $153,990.31 397
PY2025 $108,304.22 297

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $385,984.57 23
PY2024 Recipient $9,347.99 7
PY2024 Principal investigator $238,459.46 13
PY2023 Principal investigator $91,293.14 38
PY2022 Principal investigator $53,993.11 48
PY2021 Principal investigator $94,585.39 70
PY2020 Recipient $25.50 1
PY2020 Principal investigator $162,819.51 91
PY2019 Principal investigator $213,352.78 106

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $22,950.00 12/04/2025 Non-covered Recipient Entity
SCLA MANAGEMENT LLC
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202528660
Principal investigator 1 ABBVIE INC. $1,058.55 12/04/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202528662
Principal investigator 1 ABBVIE INC. $2,647.60 12/04/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202528664
Principal investigator 1 UCB SA $25.46 12/03/2025 Non-covered Recipient Entity
Sunvalley Arthritis Center, Ltd
An open-label, randomized, parallel-group, noninferiority study to evaluate the pharmacokinetics of bimekizumab administered intravenously or subcutaneously in study participants with active psoriatic arthritis and/or active axial spondyloarthritis. No dispute reported 06/30/2026 1246656903
Principal investigator 1 UCB SA $12,661.95 11/18/2025 Non-covered Recipient Entity
Sunvalley Arthritis Center, Ltd
An open-label, randomized, parallel-group, noninferiority study to evaluate the pharmacokinetics of bimekizumab administered intravenously or subcutaneously in study participants with active psoriatic arthritis and/or active axial spondyloarthritis. No dispute reported 06/30/2026 1246658878
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190308086
Principal investigator 1 ABBVIE INC. $2,424.40 10/09/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202515305
Principal investigator 1 Novartis Pharmaceuticals Corporation $62.66 10/08/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190308090
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,138.65 10/08/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190308094
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,275.07 09/19/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190308096
Principal investigator 1 ABBVIE INC. $2,196.35 09/03/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202507753
Principal investigator 1 ABBVIE INC. $36.00 07/02/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202494227
Principal investigator 1 ABBVIE INC. $1,985.15 06/03/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202489463
Principal investigator 1 ABBVIE INC. $2,388.40 06/03/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202489561
Principal investigator 1 Eli Lilly and Company $1,374.00 05/23/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER LTD
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187892944
Principal investigator 1 ABBVIE INC. $3,250.00 04/15/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202476567
Principal investigator 1 ABBVIE INC. $2,683.60 04/03/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202473325
Principal investigator 1 ABBVIE INC. $85.80 04/03/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202473330
Principal investigator 1 ABBVIE INC. $615.00 04/03/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202473739
Principal investigator 1 ABBVIE INC. $1,649.65 03/06/2025 Non-covered Recipient Entity
SUNVALLEY ARTHRITIS CENTER
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202458890
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,081.74 01/15/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190308088
Principal investigator 1 Novartis Pharmaceuticals Corporation $284,693.82 01/07/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190308092
Principal investigator 1 ABBVIE INC. $2,683.60 01/02/2025 Non-covered Recipient Entity
SUN VALLEY ARTHRITIS CENTER
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202434735